

THE FDA-APPROVED CAR T-CELL THERAPIES

As of July 31, 2021, only one type of adoptive cell therapy, the chimeric antigen receptor (CAR) T-cell therapy, is approved by the U.S. Food and Drug Administration.



There are five distinct CAR T-cell therapies to treat different cancer types, as listed below by the year they were first approved by FDA:

2021

Idecabtagene vicleucel (Abecma) to treat adult patients with relapsed or refractory multiple myeloma.

Lisocabtagene maraleucel (Breyanzi) to treat adult patients with certain types of B-cell lymphoma.

2020

Brexucabtagene autoleucel (Tecartus) to treat patients with relapsed or refractory mantle cell lymphoma.

2017

Tisagenlecleucel (Kymriah) to treat adults with certain types of B-cell lymphoma and young adult patients up to age 25 with certain types of lymphoblastic leukemia.

Axicabtagene ciloleucel (Yescarta) to treat adult patients with certain types of B-cell lymphoma.

These treatments have transformed the lives of many pediatric and adult patients with cancer.